Study protocol for FAXAge: a randomized, controlled clinical trial of fasting and exercise to slow aging in humans.

GeroscienceJun 29, 2026 (epub)
Clinical ResearchGeriatricsOpen access

Emma Bundgård Fals, Emilie Caroline Springborg, Adam Bjørnholdt Berthelsen et al.

✦ AI-curated · Sources linked

In 30 seconds

The FAXAge study is a randomized controlled trial investigating the effects of fasting and exercise on biological aging in 240 healthy adults aged 65 and older. Over 52 weeks, participants will be assigned to one of four groups: exercise, time-restricted feeding, a combination of both, or a control group. The primary outcome is the Dunedin Pace of Aging DNA methylation age.

Key findings

  • 240 healthy adults aged 65 and above will participate in the trial.
  • The study will assess outcomes at baseline, 3, 6, and 12 months, with long-term follow-ups at 2, 5, and 10 years.
  • Primary outcome measure is the Dunedin Pace of Aging DNA methylation age.

Why it matters

Understanding the impact of fasting and exercise on biological aging could inform strategies to mitigate age-related diseases and improve healthspan in older adults, a growing demographic in healthcare.

Source

PubMed · PMID 42373885Free full text on PubMed Central

Published in Geroscience. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.